logotype

Food Labelling
Services

Online Specification and Labeling Services

EC opinion deems HMO safe to place on market as Novel Food

6th April 2020


EC opinion deems HMO safe to place on market as Novel Food

The European Commission (EC) is to allow lacto-N-tetraose (LNT) to be placed on the market as a Novel Food for use in food supplements and infant product formulations.

The European Commission (EC) is to allow lacto-N-tetraose (LNT) to be placed on the market as a Novel Food for use in food supplements and infant product formulations

 

You can read the full article HERE

 

Food Labelling Services comments:

A novel food is defined as ‘foods and food ingredients that have not been used for human consumption to a significant degree in the EU before 15 May 1997’. Novel foods have to be authorised in the Novel Foods Catalogue.

LNT is a Human Milk Oligosaccharide (HMO) that s found in human breast milk. It can also be obtained by microbial fermentation with a genetically modified strain of E. Coli. Approved benefits include reducing infection by inhibiting pathogenic bacteria and their toxins and supporting gut health. 

There is a maximim limit of 0.8g/l in infant formula, and specific warnings have to be declared as part of the conditions.

 

 



This site uses some unobtrusive cookies to store information on your computer. By using our site you accept our Terms And Conditions and Privacy Policy. ×